Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TECX Stock Forecast 2026-2027
$27.64
Current Price
$518.99M
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TECX Price Targets
+265.4%
To High Target of $101.00
+175.0%
To Median Target of $76.00
+117.1%
To Low Target of $60.00
TECX Price Momentum
-6.9%
1 Week Change
-7.5%
1 Month Change
+41.8%
1 Year Change
+32.5%
Year-to-Date Change
-23.3%
From 52W High of $36.03
+92.1%
From 52W Low of $14.39
📊 TOP ANALYST CALLS
Did TECX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Tectonic Therapeutic is one of their latest high-conviction picks.
Latest TECX Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, TECX has a bullish consensus with a median price target of $76.00 (ranging from $60.00 to $101.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $27.64, the median forecast implies a 175.0% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Tiago Fauth at Wells Fargo, projecting a 265.4% upside. Conversely, the most conservative target is provided by Danielle Brill at Truist Securities, suggesting a 117.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TECX Analyst Ratings
9
Buy
0
Hold
0
Sell
TECX Price Target Range
Low
$60.00
Average
$76.00
High
$101.00
Current: $27.64
Latest TECX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TECX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 14, 2026 | Stifel | James Condulis | Buy | Initiates | $75.00 |
| Jan 8, 2026 | Truist Securities | Danielle Brill | Buy | Maintains | $60.00 |
| Sep 3, 2025 | Oppenheimer | Leland Gershell | Outperform | Initiates | $80.00 |
| Jul 21, 2025 | Truist Securities | Danielle Brill | Buy | Initiates | $64.00 |
| Jun 11, 2025 | Raymond James | Michael Freeman | Outperform | Reinstates | $76.00 |
| Jun 6, 2025 | LifeSci Capital | Outperform | Initiates | $87.00 | |
| May 15, 2025 | Mizuho | Uy Ear | Outperform | Maintains | $85.00 |
| Apr 21, 2025 | Mizuho | Uy Ear | Outperform | Initiates | $51.00 |
| Mar 21, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $101.00 |
| Jan 31, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $112.00 |
| Nov 20, 2024 | Raymond James | Danielle Brill | Outperform | Initiates | $65.00 |
| Nov 12, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $79.00 |
| Nov 11, 2024 | Leerink Partners | David Risinger | Outperform | Maintains | $69.00 |
| Aug 22, 2024 | Wells Fargo | Tiago Fauth | Overweight | Initiates | $55.00 |
| Jul 24, 2024 | Leerink Partners | David Risinger | Outperform | Initiates | $49.00 |
| Jun 26, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Initiates | $76.00 |
| Jun 24, 2024 | TD Cowen | Tyler Van Buren | Buy | Initiates | $N/A |
Tectonic Therapeutic Inc. (TECX) Competitors
The following stocks are similar to Tectonic Therapeutic based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TECX
Tectonic Therapeutics
mkt cap
554.10M
Tectonic Therapeutic Inc. (TECX) Financial Data
Tectonic Therapeutic Inc. has a market capitalization of $518.99M with a P/E ratio of 4.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -37.8%.
Valuation Metrics
Market Cap
$518.99M
Enterprise Value
$287.49M
P/E Ratio
4.6x
PEG Ratio
0.2x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+48.9%
Current Ratio
26.6x
Debt/Equity
0.5x
ROE
-37.8%
ROA
-25.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Tectonic Therapeutic Inc. (TECX) Business Model
About Tectonic Therapeutic Inc.
What They Do
Develops transformative therapies for complex diseases.
Business Model
Tectonic Therapeutic generates revenue through the discovery and development of novel drugs aimed at addressing unmet medical needs. The company collaborates with research institutions and industry partners to advance therapeutic programs, thereby positioning itself to potentially benefit from licensing agreements, partnerships, and future product sales.
Additional Information
The company is recognized in the biotechnology and healthcare sectors for its innovative approach and commitment to precision medicine. Tectonic Therapeutic's focus on cutting-edge research and proprietary techniques enhances its potential to improve patient outcomes and gain traction in the highly competitive biotech market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
60
CEO
Dr. Alise S. Reicin M.D., Ph.D.
Country
United States
IPO Year
2018
Website
tectonictx.comTectonic Therapeutic Inc. (TECX) Latest News & Analysis
Latest News
Quick Summary
Tectonic Therapeutics is advancing TX45 for Group 2 Pulmonary Hypertension, showing promise in phase 1b trials. With $253.8M cash, they are funded for phase 2, targeting $0.6B–$1.8B in U.S. sales.
Why It Matters
Tectonic Therapeutics' TX45 targets a large market with promising phase 1b results and ample funding for phase 2, presenting significant revenue potential that can boost investor confidence.
Source: Seeking Alpha
Market Sentiment:
Positive
Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
1 month ago
Quick Summary
Tectonic Therapeutic, Inc. (TECX) presented at the TD Cowen 46th Annual Health Care Conference, highlighting key developments and insights relevant to investors.
Why It Matters
Tectonic Therapeutics' presentation could impact investor sentiment and stock performance by providing insights into its pipeline, financial health, and strategic direction in the healthcare sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Tectonic Therapeutic, Inc. (NASDAQ: TECX) reported its Q4 and full year financial results for 2025, focusing on GPCR-targeting therapeutic proteins and antibodies.
Why It Matters
Tectonic Therapeutic's financial results and business updates can influence stock performance, signaling potential growth or risk, impacting investor sentiment and decision-making.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
1 month ago
Quick Summary
Tectonic Therapeutic, Inc. (NASDAQ: TECX) has appointed François Nader, M.D., MBA, as an independent director and Chair of the Board, effective April 1, 2026.
Why It Matters
The appointment of François Nader as Chair could signal strategic leadership changes, impacting Tectonic's direction and potential growth in the biotech sector, influencing investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tectonic Therapeutic, Inc. (NASDAQ: TECX) will host a virtual key opinion leader event on February 24, 2026, to discuss its TX2100 program.
Why It Matters
Tectonic Therapeutic's KOL event may signal advancements in their drug pipeline, particularly TX2100. Positive developments could impact stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tectonic Therapeutics reported positive phase 1b results for PH-HFrEF. It is advancing in phase 2 APEX for CpcPH, with topline data due in 2026. The company has $268.4M cash to fund operations through Q4 2028.
Why It Matters
Tectonic Therapeutic's positive study results and strong cash position indicate potential for future growth and clinical advancements, making it a company to watch for investors interested in biotech.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About TECX Stock
What is Tectonic Therapeutic Inc.'s (TECX) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Tectonic Therapeutic Inc. (TECX) has a median price target of $76.00. The highest price target is $101.00 and the lowest is $60.00.
Is TECX stock a good investment in 2026?
According to current analyst ratings, TECX has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $27.64. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TECX stock?
Wall Street analysts predict TECX stock could reach $76.00 in the next 12 months. This represents a 175.0% increase from the current price of $27.64. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tectonic Therapeutic Inc.'s business model?
Tectonic Therapeutic generates revenue through the discovery and development of novel drugs aimed at addressing unmet medical needs. The company collaborates with research institutions and industry partners to advance therapeutic programs, thereby positioning itself to potentially benefit from licensing agreements, partnerships, and future product sales.
What is the highest forecasted price for TECX Tectonic Therapeutic Inc.?
The highest price target for TECX is $101.00 from Tiago Fauth at Wells Fargo, which represents a 265.4% increase from the current price of $27.64.
What is the lowest forecasted price for TECX Tectonic Therapeutic Inc.?
The lowest price target for TECX is $60.00 from Danielle Brill at Truist Securities, which represents a 117.1% increase from the current price of $27.64.
What is the overall TECX consensus from analysts for Tectonic Therapeutic Inc.?
The overall analyst consensus for TECX is bullish. Out of 10 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $76.00.
How accurate are TECX stock price projections?
Stock price projections, including those for Tectonic Therapeutic Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 3:56 AM UTC